Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 120

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 5
Chunk 120
---
 expenses were JPY 1,053.0 billion (JPY +55.6 billion and +5.6% AER, +0.8% CER). The increase was mainly due to the depreciation of Japanese yen and investments in DD& T partially offset by various cost efficiencies.

Core Research and Development (R& D) Expenses

Core R& D expenses were JPY 729.6 billion (JPY +96.3 billion and +15.2% AER, +8.3% CER). The increase was mainly due to various investments in pipeline programs and the depreciation of Japanese yen.

Table of Contents

Core Net Profit for the Year

Core Net Profit for the Year was JPY 756.9 billion (JPY -109.5 billion and -12.6% AER, -15.0% CER) and is calculated from Core Operating Profit are as below:

                                                                                 Billion JPY or percentage                                                                                           
                                                                                 For the fiscal year ended                                             AER                                 CER       
                                                                                 March 31,                                                                                                           
                                                                                 2023                                           2024                   Amount of Change      % Change      % Change  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Core operating profit                                                          ¥                              1,188.4            ¥      1,054.9      ¥                       (11.2)      (13.3)    
  Core finance income and (expenses), net                                        (126.6)                                     (142.0)                   (15.4)                    12.2      13.9      
  Core share of profit of investments accounted for using the equity method      0.2                                             5.9                   5.7                          ―      ―         
  Core profit before tax                                                                                        1,062.0        918.8                   (143.2)                 (13.5)      (16.0)    
  Core income tax expenses                                                       (195.6)                                     (161.9)                   33.7                    (17.2)      (20.2)    
  Core net profit for the year                                                   866.4                                         756.9                   (109.5)                 (12.6)      (15.0)    
  Core net profit for the year attributable to owners of the Company             ¥                                866.4            ¥        756.8      ¥                       (12.